New antibody drug shows promise for Hard-to-Treat myeloma

NCT ID NCT05714839

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a drug called belantamab, given alone or with other treatments, in people with multiple myeloma. The trial has three parts: first, finding a safe dose; second, testing combinations; third, comparing the best option to standard care. About 152 participants will be enrolled to see if the drug is safe and helps control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab (an antibody drug)
What this could lead to: If successful, this could provide a new treatment option for multiple myeloma patients who have not responded to prior therapies.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply broadly. Side effects, including eye problems, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Bullhead City, Arizona, 86442, United States
GSK Investigational Site
RECRUITING

Pembroke Pines, Florida, 33024, United States
GSK Investigational Site
RECRUITING

Grand Rapids, Michigan, 49546, United States
GSK Investigational Site
RECRUITING

Chapel Hill, North Carolina, 27514, United States
GSK Investigational Site
RECRUITING

Wilson, North Carolina, 27893, United States
GSK Investigational Site
RECRUITING

Canton, Ohio, 44718, United States
GSK Investigational Site
RECRUITING

Chattanooga, Tennessee, 37404, United States
GSK Investigational Site
RECRUITING

Nashville, Tennessee, 37203, United States
GSK Investigational Site
COMPLETED

Ciudadela, B1702, Argentina
GSK Investigational Site
RECRUITING

Rosario, S2002, Argentina
GSK Investigational Site
RECRUITING

San Juan Bautista, B1888AAE, Argentina
GSK Investigational Site
RECRUITING

Viedma, R8500ACE, Argentina
GSK Investigational Site
RECRUITING

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site
COMPLETED

Nedlands, Western Australia, 6009, Australia
GSK Investigational Site
RECRUITING

Joinville, 89201-260, Brazil
GSK Investigational Site
RECRUITING

Salvador, 41253-190, Brazil
GSK Investigational Site
RECRUITING

São Paulo, 04537-080, Brazil
GSK Investigational Site
RECRUITING

Jerusalem, 9112001, Israel
GSK Investigational Site
RECRUITING

Aomori, 030-8553, Japan
GSK Investigational Site
RECRUITING

Chiba, 277-8577, Japan
GSK Investigational Site
RECRUITING

Kanagawa, 221-0855, Japan
GSK Investigational Site
COMPLETED

Osaka, 545-8586, Japan
GSK Investigational Site
RECRUITING

Tokyo, 105-8471, Japan
GSK Investigational Site
RECRUITING

Yamagata, 990-9585, Japan
GSK Investigational Site
WITHDRAWN

Gdansk, 80-214, Poland
GSK Investigational Site
RECRUITING

Lublin, 20-081, Poland
GSK Investigational Site
RECRUITING

Seoul, 137-701, South Korea
GSK Investigational Site
RECRUITING

Seoul, 138-736, South Korea
GSK Investigational Site
RECRUITING

Changhua, 500, Taiwan
GSK Investigational Site
RECRUITING

Kaohsiung City, 807, Taiwan
GSK Investigational Site
RECRUITING

Taipei, 100, Taiwan
GSK Investigational Site
RECRUITING

Istanbul, 34010, Turkey (Türkiye)
GSK Investigational Site
RECRUITING

Kayseri, 38039, Turkey (Türkiye)
GSK Investigational Site
RECRUITING

Leicester, LE1 5WW, United Kingdom
GSK Investigational Site
COMPLETED

Oxford, OX3 7LE, United Kingdom
GSK Investigational Site
RECRUITING

Plymouth, PL6 8DH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.